Evaluation of Efficacy and Tolerabilty of MelaB3 Serum in Combination of 35% Glycolic Acid Peelin… (NCT07429786) | Clinical Trial Compass
Not Yet RecruitingNot Applicable
Evaluation of Efficacy and Tolerabilty of MelaB3 Serum in Combination of 35% Glycolic Acid Peeling Compared to 35% Glycolic Acid Peeling Alone in Various Hyperpigmentation Conditions
80 participantsStarted 2026-03-04
Plain-language summary
Randomized clinical trial to assess the effectiveness and tolerability of Mela B3 serum in combination with 35% glycolic acid peel vs. 35% glycolic acid peel for the treatment of various hyperpigmentation conditions (melasma, post-inflammatory hyperpigmentation and solar lentigo) and signs of aging in a population of participants from the Autonomous City of Buenos Aires, Argentina.
Who can participate
Age range30 Years – 70 Years
SexALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion criteria
✓. Women and men
✓. From 30 to 70 years of age (inclusive)
✓. Good general health
✓. With any type of phototype
✓. Hyperpigmentation condition with average darkness \> 3:
✓. Epidermal or mixed melasma (determined by Wood's lamp examination at screening), mild to moderate melasma (IGA 1 or 2)
✓. Post acne inflammatory hyperpigmentation (PIHP), mild to moderate (IGA 1 or 2) with no active acne and less than 10 inflammatory lesion on full face
✓. Solar lentigo (SL) with a pigmentation score\>5
Exclusion criteria
✕. Pregnant, breastfeeding or with pregnancy plans.
✕. All contraindications for superficial peeling (for example, concomitant infectious processes or inflammatory processes that affect the skin barrier).
✕. Melasma with predominance of the pigmentary component at the dermis level, observed with Wood's light at the inclusion visit.
✕. Active acne with 10 or more inflammatory lesions.
✕. In the case of melasma, participants with recent change of contraception (less than 3 months) or less than 3 months since childbirth.